Vigil Neuroscience stock slips on trial setback (VIGL:NASDAQ)
Richard Drury Vigil Neuroscience (NASDAQ:VIGL) announced on Wednesday that a mid-stage trial for its lead candidate, iluzanebart, didn’t succeed in patients with a rare neurological disease called adult-onset leukoencephalopathy with…
Share